S3F0.F SANTHERA PHARM.HD.SF 0,10
- Market cap
- EUR 246M
- P/E
- -
- P/B
- 6.57x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is S3F0.F undervalued?
Graham numberThe Graham number of SANTHERA PHARM.HD.SF 0,10 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SANTHERA PHARM.HD.SF 0,10 fundamental analysis
No fundamental analysis for SANTHERA PHARM.HD.SF 0,10 yet.
SANTHERA PHARM.HD.SF 0,10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SANTHERA PHARM.HD.SF 0,10
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Full company profileSANTHERA PHARM.HD.SF 0,10 financial statements
SANTHERA PHARM.HD.SF 0,10 annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 7.47M | 103M | 39.1M | 77.2M |
| Gross Profit | 3.88M | 100M | 23.6M | 15.2M |
| Operating Income | -52.0M | 51.2M | -33.2M | -37.6M |
| EBITDA | -40.6M | 79.2M | -28.2M | -31.8M |
| Net Income | -71.1M | 54.8M | -42.0M | -49.2M |
| EPS | -11 | 4.84 | -3.28 | -3.68 |
| Balance Sheet | ||||
| Total Assets | 63.7M | 110M | 152M | 148M |
| Total Liabilities | 107M | 49.7M | 125M | 160M |
| Shareholders' Equity | -43.7M | 59.9M | 27.7M | -11.8M |
| Cash & Short-term Investments | 1.35M | 30.4M | 40.9M | 22.4M |
| Cash Flow | ||||
| Operating Cash Flow | -29.8M | 47.3M | -35.5M | -34.8M |
| Capital Expenditure | 3.96M | 23.7M | 151K | 52.0K |
| Free Cash Flow | -33.8M | 23.5M | -35.7M | -34.8M |
| Ratios | ||||
| ROE | - | 91.4% | -151.5% | - |
| ROA | -111.5% | 50.0% | -27.5% | -33.2% |
| Net Profit Margin | -951.1% | 53.0% | -107.3% | -63.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SANTHERA PHARM.HD.SF 0,10 dividends
SANTHERA PHARM.HD.SF 0,10 has not paid dividends in the last 4 fiscal years.
Last stock split: 1:10 on Jul 3, 2023.
Who owns SANTHERA PHARM.HD.SF 0,10
- Insiders 11.15%
- Institutions 16.77%
- Public & others 72.09%
- Shares outstanding 15.3M
- Free float 12.6M
SANTHERA PHARM.HD.SF 0,10 company profile
- Company name
- SANTHERA PHARM.HD.SF 0,10
- Ticker
- S3F0.F
- ISIN
- CH1276028821
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 93
- Fiscal year end
- December
- Address
- Hohenrainstrasse 24, Pratteln, Switzerland, 4133
- Phone
- 41 61 906 89 50
- Website
- santhera.com
About SANTHERA PHARM.HD.SF 0,10
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
SANTHERA PHARM.HD.SF 0,10 management
10- Dr. Thomas Meier Ph.D.Founder & Chairman · born 1962
- Dr. Shabir Hasham M.D.Chief Medical Officer · born 1970
- Mr. Orlando OliveiraChief Executive Officer · born 1976
- Ms. Catherine Ann Isted A.C.M.A.Chief Financial Officer · born 1975
- Mr. Marc SchraderChief Technology Officer · born 1971
- Mr. Oliver StrubHead of Compliance · born 1963
- Dr. Oliver P. Kronenberg Ph.D.Chief Legal Officer & Corporate Secretary · born 1968
- Mr. Neville Kodkani M.D.Head of Global Marketing & Partner Management
- Ms. Sarah Holmes-KlotzGlobal Head of People & Culture
- Mr. Andreas MissySVP of Corporate Planning & Business Development